Disease · MONDO_0001187
urinary bladder cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. urinary bladder cancer. Diseases, record MONDO_0001187. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001187
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
bladder cancer, somatic, cancer of urinary bladder, malignant bladder neoplasm, malignant bladder tumor, malignant bladder tumour, malignant neoplasm of bladder, malignant neoplasm of the bladder, malignant neoplasm of the urinary bladder, malignant neoplasm of urinary bladder, malignant neoplasm, bladder, malignant neoplasm, urinary bladder, malignant tumor of bladder, malignant tumor of the bladder, malignant tumor of the urinary bladder, malignant tumor of urinary bladder, malignant tumor, urinary bladder, malignant tumour of bladder, malignant tumour of the bladder, malignant tumour of the urinary bladder, malignant tumour of urinary bladder, malignant urinary bladder neoplasm, malignant urinary bladder tumor, malignant urinary bladder tumour, urinary bladder malignant neoplasm, urinary bladder malignant tumor, urinary bladder malignant tumour
- Open Targets
Drugs87
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 31 | 31 | 31 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 30 | 30 | 30 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| BCG VACCINE | CHEMBL2108905 | Vaccine component | Phase 3 | ClinicalTrials.gov | 8 | 8 | 5 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BCG LIVE | CHEMBL2108020 | Phase 3 | ClinicalTrials.gov | 6 | 6 | 0 | Drugs and targets | |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 87
See all 87 drugsTargets146
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TUBA1A | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/81027 | Drugs and targets |
| TUBB2A | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7280 | Drugs and targets |
| TUBB2B | Tubulin | 7 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/347733 | Drugs and targets |
1 to 10 of 146
See all 146 targetsTrials121
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04165317 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Phase 3 | 1,068 | 2026-01-22 | Non-muscle Invasive Bladder Cancer | BCG VACCINE, SASANLIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00598806 | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) | Phase 3 | 812 | 2017-08-15 | Bladder Cancer | APAZIQUONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00461591 | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) | Phase 3 | 802 | 2017-08-15 | Bladder Cancer | APAZIQUONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | Phase 3 | 521 | 2017-06-08 | Bladder Cancer | CISPLATIN, DOXORUBICIN, METHOTREXATE, VINBLASTINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | 260 | 2021-09-30 | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | NUMIDARGISTAT, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04209114 | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer | Phase 3 | 114 | 2024-06-27 | Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer | BEMPEGALDESLEUKIN, NIVOLUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | Phase 2 | 97 | 2016-08-10 | Bladder Cancer | CISPLATIN, FLUOROURACIL, GEMCITABINE, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | Phase 1/2 | 92 | 2022-02-28 | Bladder Cancer | CISPLATIN, ERIBULIN MESYLATE, GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | Phase 1/2 | 83 | 2025-03-18 | Urothelial Carcinoma, Bladder Cancer | CISPLATIN, GEMCITABINE, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Phase 2 | 81 | 2025-07-22 | Bladder Cancer, Melanoma | IPILIMUMAB, NIVOLUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 121
See all 121 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Apaziquone vs Placebo: deaths from any cause | 14 of 402 | 14 of 410 | 812 | NCT00598806 | Trial comparisons |
| Apaziquone vs Placebo: serious adverse events | 96 of 402 | 108 of 410 | 812 | NCT00598806 | Trial comparisons |
| Apaziquone vs Placebo: deaths from any cause | 11 of 406 | 13 of 396 | 802 | NCT00461591 | Trial comparisons |
| Apaziquone vs Placebo: serious adverse events | 93 of 406 | 98 of 396 | 802 | NCT00461591 | Trial comparisons |
| Pelvic RT + Paclitaxel + Cisplatin vs Pelvic RT + Fluorouracil + Cisplatin: serious adverse events | 43 of 46 | 39 of 47 | 93 | NCT00055601 | Trial comparisons |
| Melanoma Cancer Patients vs Bladder Cancer Patients: deaths from any cause | 2 of 10 | 51 of 69 | 79 | NCT02553642 | Trial comparisons |
| Melanoma Cancer Patients vs Bladder Cancer Patients: serious adverse events | 10 of 10 | 69 of 69 | 79 | NCT02553642 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: Number of Participants With Serious Adverse Events (SAEs) | 2 of 20 | 2 of 19 | 39 | NCT04197986 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: Number of Participants With Adverse Events (AEs) | 19 of 20 | 16 of 19 | 39 | NCT04197986 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: deaths from any cause | 2 of 20 | 1 of 19 | 39 | NCT04197986 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials99
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001187
GET https://conductscience.org/api/diseases/v1/MONDO_0001187/drugs?page=2